Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T Dorr

Showing results (31-40 of 156) with videos related to

Pageof 16
Sort By:
Anticancer Research|January 1, 1988
Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in miceM J Soble, R T Dorr
Cancer|August 15, 1992
Topical absorption and inactivation of cytotoxic anticancer agents in vitroR T Dorr, D S Alberts
Investigational New Drugs|January 1, 1983
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluentsR T Dorr, D S Alberts
Cancer Research|June 1, 1981
Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compoundsR T Dorr, D S Alberts
Cancer Treatment Reviews|January 1, 1995
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionP E Kintzel, R T Dorr
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Cimetidine enhances cisplatin toxicity in miceR T Dorr, M J Soble
Medical and Pediatric Oncology|January 1, 1979
Inapparent infiltrations associated with vindesine administrationR T Dorr, S E Jones
Research Communications in Chemical Pathology and Pharmacology|February 1, 1987
Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in miceM J Soble, R T Dorr
Cancer Drug Delivery|January 1, 1987
Schedule-dependent toxicity of tumor necrosis factor in rodentsJ D Liddil, R T Dorr
British Journal of Cancer|January 1, 1982
Cimetidine enhancement of cyclophosphamide antitumour activityR T Dorr, D S Alberts
Pageof 16

Showing results (31-40 of 156) with videos related to

Sort By:
Pageof 16
Anticancer Research|January 1, 1988
Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in miceM J Soble, R T Dorr
Cancer|August 15, 1992
Topical absorption and inactivation of cytotoxic anticancer agents in vitroR T Dorr, D S Alberts
Investigational New Drugs|January 1, 1983
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluentsR T Dorr, D S Alberts
Cancer Research|June 1, 1981
Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compoundsR T Dorr, D S Alberts
Cancer Treatment Reviews|January 1, 1995
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionP E Kintzel, R T Dorr
Journal of Cancer Research and Clinical Oncology|January 1, 1988
Cimetidine enhances cisplatin toxicity in miceR T Dorr, M J Soble
Medical and Pediatric Oncology|January 1, 1979
Inapparent infiltrations associated with vindesine administrationR T Dorr, S E Jones
Research Communications in Chemical Pathology and Pharmacology|February 1, 1987
Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in miceM J Soble, R T Dorr
Cancer Drug Delivery|January 1, 1987
Schedule-dependent toxicity of tumor necrosis factor in rodentsJ D Liddil, R T Dorr
British Journal of Cancer|January 1, 1982
Cimetidine enhancement of cyclophosphamide antitumour activityR T Dorr, D S Alberts
Pageof 16